ACADIA Pharmaceuticals Inc. (ACAD)

40.45
NASDAQ : Health Technology
Prev Close 39.14
Day Low/High 39.60 / 41.24
52 Wk Low/High 13.51 / 43.98
Avg Volume 1.77M
Exchange NASDAQ
Shares Outstanding 144.49M
Market Cap 5.66B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Revisiting 3 Promising Small Biotechs

Revisiting 3 Promising Small Biotechs

They are oversold and lately been on the move.

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

Acadia's Parkinson's drug Nuplazid clears key hurdle

Acadia's Parkinson's drug Nuplazid clears key hurdle

Acadia could rake in $2 billion in revenue from Nuplazid

Why Acadia (ACAD) Stock is Still Soaring Today

Why Acadia (ACAD) Stock is Still Soaring Today

Acadia (ACAD) shares are flying on heavy trading volume Wednesday as the company's key drug in its portfolio is one step closer to being approved by the FDA.

4 Big-Volume Stocks to Trade for Big Gains

4 Big-Volume Stocks to Trade for Big Gains

These stocks are seeing unusually large trading volume today. Here's what to do with them now.

Acadia (ACAD) Stock Skyrockets, Parkinson's Disease Drug Backed by FDA Advisory Panel

Acadia (ACAD) Stock Skyrockets, Parkinson's Disease Drug Backed by FDA Advisory Panel

Acadia (ACAD) shares are surging on Wednesday after the advisory panel to the Food and Drug Administration voted in favor of a key drug in the company's portfolio.

FDA Advisory Committee Votes 12 To 2 That Benefits Of ACADIA Pharmaceuticals' NUPLAZID™ (Pimavanserin) For The Treatment Of Psychosis Associated With Parkinson's Disease Outweigh The Risks

FDA Advisory Committee Votes 12 To 2 That Benefits Of ACADIA Pharmaceuticals' NUPLAZID™ (Pimavanserin) For The Treatment Of Psychosis Associated With Parkinson's Disease Outweigh The Risks

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Acadia Pharma FDA Advisory Panel Live Blog

Acadia Pharma FDA Advisory Panel Live Blog

A panel of outside experts selected by the FDA are reviewing a Parkinson's disease drug developed by Acadia Pharmaceuticals.

ACADIA Pharmaceuticals Stock Trading Halted Today

ACADIA Pharmaceuticals Stock Trading Halted Today

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

7 Stocks Seeing Big Volume Today -- and How You Should Trade Them Now

7 Stocks Seeing Big Volume Today -- and How You Should Trade Them Now

Here's a technical look at how to trade some of the most active stocks on the market right now.

3 Drugs Stocks Driving The Industry Higher

3 Drugs Stocks Driving The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Acadia Pharmaceuticals (ACAD) Stock Soars Ahead of Tuesday Panel

Acadia Pharmaceuticals (ACAD) Stock Soars Ahead of Tuesday Panel

Acadia Pharmaceuticals (ACAD) stock is surging on Monday morning ahead of tomorrow’s meeting of experts chosen by the FDA to discuss the company’s Nuplazid drug.

ACADIA Pharmaceuticals (ACAD): Heavy Pre-Market Activity

ACADIA Pharmaceuticals (ACAD): Heavy Pre-Market Activity

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a pre-market mover with heavy volume candidate

U.S. Futures Have Strong Start to Week

U.S. futures are climbing Monday after major indices experienced a dip in trading last week.

Acadia's Parkinson's Drug Hit With Critical FDA Review Ahead of Tuesday Panel

Acadia's Parkinson's Drug Hit With Critical FDA Review Ahead of Tuesday Panel

The outcome of the panel vote is very important to Acadia. An affirmative decision would most likely compel the FDA to approve Nuplazid by its decision date of May 1.

Biotech Stock Mailbag: How to Spot Red Flags in Clinical Trial Data

Biotech Stock Mailbag: How to Spot Red Flags in Clinical Trial Data

TheStreet's senior columnist Adam Feuerstein answers reader questions about biotech stocks.

ACADIA Pharmaceuticals (ACAD) Highlighted As Today's Perilous Reversal Stock

ACADIA Pharmaceuticals (ACAD) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "perilous reversal" (up big yesterday but down big today) candidate

There Are Reasons for Acadia Investors to Be Optimistic About Nuplazid and the Company

There Are Reasons for Acadia Investors to Be Optimistic About Nuplazid and the Company

The FDA advisory committee is meeting on March 29 to discuss the future of Nuplazid, a drug for the potential treatment of Parkinson Disease Psychosis. There's reason to be optimistic.

Tesla, Amazon and Netflix: Doug Kass' Views

Tesla, Amazon and Netflix: Doug Kass' Views

Doug Kass shares his views on why technicals bode ill for tech.

Biotech Stock Mailbag: Acadia, Relypsa, Celator

Biotech Stock Mailbag: Acadia, Relypsa, Celator

TheStreet's biotech columnist Adam Feuerstein answers reader questions about biotech stock investing.

Small-Cap Friday: ACADIA Pharmaceuticals

Small-Cap Friday: ACADIA Pharmaceuticals

I like the biopharma's risk/reward on potential sales of Nuplazid.

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's "Perilous Reversal" Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "perilous reversal" (up big yesterday but down big today) candidate

ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock

ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate

ACADIA Pharmaceuticals To Present At The Cowen And Company 36th Annual Health Care Conference On March 8, 2016

ACADIA Pharmaceuticals To Present At The Cowen And Company 36th Annual Health Care Conference On March 8, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2015

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a weak on high relative volume candidate

ACADIA Pharmaceuticals To Present At The LEERINK Partners 5th Annual Global Healthcare Conference On February 10, 2016

ACADIA Pharmaceuticals To Present At The LEERINK Partners 5th Annual Global Healthcare Conference On February 10, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

TheStreet Quant Rating: D (Sell)